Drug Information

Drug (ID: DG01760) and It's Reported Resistant Information

• Name: Buparlisib/Vemurafenib
• Synonyms: Buparlisib/Vemurafenib
• Target: .; NOUNIPROTAC; [1]

Type(s) of Resistant Mechanism of This Drug

  ADTT: Aberration of the Drug's Therapeutic Target

Drug Resistance Data Categorized by Their Corresponding Diseases

ICD-02: Benign/in-situ/malignant neoplasm

Melanoma [ICD-11: 2C30]

Drug Sensitivity Data Categorized by Their Corresponding Mechanisms

Aberration of the Drug's Therapeutic Target (ADTT)

Key Molecule: Serine/threonine-protein kinase B-raf (BRAF) [1]

• Molecule Alteration: Missense mutation; p.V600X (c.1798_1800)
• Sensitive Disease: Melanoma [ICD-11: 2C30.0]
• Experimental Note: Revealed Based on the Cell Line Data
• In Vitro Model: A375 cells; Skin; Homo sapiens (Human); CVCL_0132
• In Vitro Model: Melanoma cells; Skin; Homo sapiens (Human); N.A.
• In Vitro Model: WM cells; N.A.; Homo sapiens (Human); N.A.
• In Vitro Model: SK cells; Brain; Homo sapiens (Human); N.A.
• Experiment for Molecule Alteration: Western blotting analysis
• Experiment for Drug Resistance: CellTiter-Glo assay; Fluorescent microscopy assay; Apoptosis analysis

References

• Ref 1: A novel AKT1 mutant amplifies an adaptive melanoma response to BRAF inhibitionCancer Discov. 2014 Jan;4(1):69-79. doi: 10.1158/2159-8290.CD-13-0279. Epub 2013 Nov 21.